This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
28 April 2015
In the version of this article initially published, the caption stated that Amgen's Neupogen was the first biosimilar to be approved by the FDA, rather than saying that the first biosimilar for Neupogen had been approved by the FDA. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. First US biosimilar edges towards market. Nat Biotechnol 33, 222–223 (2015). https://doi.org/10.1038/nbt0315-222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0315-222
This article is cited by
-
Celltrion's infliximab copy shows path to biosimilars in US
Nature Biotechnology (2016)
-
First US biosimilar launch
Nature Biotechnology (2015)